Scopus BioPharma (SCPS) Stock Price, News & Analysis

Company Overview

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Key Stats

• Today's Range: $0.0003 to $0.0003
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.01
• Volume: 1,000 shs
• Average Volume: 1,839 shs
• Market Capitalization: $12.62 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCPS Stock Analysis - Frequently Asked Questions

How have SCPS shares performed this year?

Scopus BioPharma's stock was trading at $0.0003 at the start of the year. Since then, SCPS shares have increased by 0.0% and is now trading at $0.0003.

How do I buy shares of Scopus BioPharma?

Shares of SCPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scopus BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scopus BioPharma investors own include Plug Power (PLUG), Canoo (GOEV), NIO (NIO), SNDL (SNDL), Tesla (TSLA), Moderna (MRNA) and VYNE Therapeutics (VYNE).

Company Calendar

• Today: 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCPS
• CIK: 1772028
• Web: scopusbiopharma.com
• Phone: 212-479-2513
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 42,080,000
• Free Float: 39,938,000
• Market Cap: $12.62 thousand
• Optionable: Not Optionable
• Beta: -0.19